Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Accounts Payables: 2020-2025

Historic Accounts Payables for Biofrontera (BFRI) over the last 4 years, with Sep 2025 value amounting to $6.6 million.

  • Biofrontera's Accounts Payables rose 40.77% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 40.77%. This contributed to the annual value of $4.3 million for FY2024, which is 4.77% down from last year.
  • Per Biofrontera's latest filing, its Accounts Payables stood at $6.6 million for Q3 2025, which was up 12.87% from $5.8 million recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Accounts Payables ranged from a high of $11.1 million in Q1 2023 and a low of $3.6 million during Q2 2024.
  • Over the past 3 years, Biofrontera's median Accounts Payables value was $4.6 million (recorded in 2024), while the average stood at $6.0 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 256.76% in 2021, then slumped by 62.01% in 2024.
  • Over the past 5 years, Biofrontera's Accounts Payables (Quarterly) stood at $9.7 million in 2021, then climbed by 12.53% to $10.9 million in 2022, then tumbled by 58.70% to $4.5 million in 2023, then declined by 4.77% to $4.3 million in 2024, then skyrocketed by 40.77% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $5.8 million for Q2 2025, and $4.6 million during Q1 2025.